I did take glutamine on its own several years ago (in addition to the BCAAs) - but - it caused insomnia so I had to stop taking it. I think it did help with energy a little bit, though it did not stop PEM. But - I've had trouble with insomnia for over 20 years. I can't take supplements or drugs which make it worse, and glutamine ended up making it worse for me. Glutamine is a precursor for both glutamate and GABA and it seems to be a crapshoot whether it's going to make sleep better or worse.
As you apparently got more energy from methylene blue which is another of many that inhibits nlrp3 just a couple below for example, perhaps that or another nlrp3 inhibitor would work was the thought. Look up supplement + nlrp3 in future. Glutamine during the day giving insomnia if that is what you tried or wish to try again without bcaas alone this time as a test reminds that sometimes it can have multiple effects to consider.
Many in vitro and in vivo studies have proved that melatonin alleviates NLRP3 inflammasome activity via various intracellular signaling pathways. Another I remember you tried
https://pmc.ncbi.nlm.nih.gov/articles/PMC8300798
hyperbaric oxygen therapy alleviates the activation of NLRP3 inflammasome
https://pmc.ncbi.nlm.nih.gov/articles/PMC5646971/
methylene blue also inhibits the NLRP3 inflammasome activation by the way.
https://www.nature.com/articles/s41598-017-12635-6
Riboflavin vitamin b2 inhibits nlrp3
https://www.nature.com/articles/s41598-020-76251-7
Butyrate lowers nlrp3,, propionate, acetate increases
https://www.sciencedirect.com/science/article/pii/S2213231718300247
Far infrared radiation (as found in PEMF mat from what I read possibly the device you tried also) inhibited the NLRP3 inflammasome as well also apparently so these all have similar mechanism of action.
https://pubmed.ncbi.nlm.nih.gov/26864306/
Ketamine is one of many that may work for ME/CFS due to inhibition of NLRP3
https://pubmed.ncbi.nlm.nih.gov/35925279/ as well as mentioned some benefit to restore impaired myelination
https://forums.phoenixrising.me/thr...ic-fatigue-syndrome.91144/page-3#post-2451679
NAC has been shown to inhibit the NLRP3 inflammasome pathway (IL1β and IL18) in vitro, and decrease plasma TNF-ɑ in human clinical trials. NAC has been used to replenish glutathione stores and increase the proliferative response of T cells - N-Acetylcysteine (NAC) is an antioxidant and a precursor of the synthesis of glutathione (GSH).
https://www.sciencedirect.com/science/article/pii/S0306987720308811 https://pubmed.ncbi.nlm.nih.gov/32504923/
Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation - NLRP3 Inflammasome activation is limited by Exogenous GSH (Glutathione) and augmented in the presence of GSTO1-1 which suggests deglutathionylation as a possible process required for NLRP3 activation.
https://www.cell.com/cell-reports/pdf/S2211-1247(19)31127-1.pdf. So maybe S-Acetyl L-Glutathione
Azithromycin accelerated NLRP3 transcript decay
https://respiratory-research.biomedcentral.com/counter/pdf/10.1186/s12931-017-0608-8.pdf
Palmitoylethanolamide PEA, doxycycline, and colchicine which all inhibit the NLRP3 inflammasome that have shown benefits may be effective.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8472716/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8466018/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10013297/
Suramin happens to be another NLRP3 inhibito
Consistently, apyrase (extracellular ATP scavenger),
suramin (P2 receptor inhibitor), TNP-ATP (P2X receptor antagonist), and 5-BDBD (P2X4 inhibitor) downregulate
NLRP3 expression
https://www.nature.com/articles/s41401-022-00886-7
Zinc deficiency activates nlrp3 and er stress but would need to try chelated zinc like solgar chelated zinc.
https://www.nature.com/articles/cddis2013547
Zinc deficiency evokes the endoplasmic reticulum (
ER)-
stress response
https://pubmed.ncbi.nlm.nih.gov/23748779/
Zinc inhibits iNOS promoter activity. NF-kB silencing abolishes cytokine-induced iNOS expression. Zinc inhibits the transactivation activity of NFκB.
https://www.sciencedirect.com/science/article/pii/S2213231714000834
P2X7 receptor (P2X7R) is required for secretion of IL-1, and can be blocked by divalent cations such as magnesium (Mg). We demonstrated that Magnesium sulfate is efficacious in blocking IL-1-mediated-inflammation in HUVECs via downregulation of P2X7Rs on HUVECs https://pubmed.ncbi.nlm.nih.gov/31493768/ epsom salt bath or foot soak or dr Clark makes pills for example
Anakinra is a bio-engineered form of the naturally occurring interleukin-1 receptor antagonist (IL-1ra) that blocks the action of interleukin-1. It is routinely used in patients with autoimmune and inflammatory disorders and MAS. Within the IL-1 family of cytokines, several inhibitory mechanisms are in place to prevent runaway inflammation induced by IL-1α or IL-1β. The main mechanism is the IL-1 receptor antagonist (IL-1Ra), which blocks the IL-1R1 and prevents binding of IL-1α and IL-1β. In contrast to JAKinibs, anakinra will not directly block the IFN-STAT1/STAT2 pathway critical for host defense against viral infections. Third, in contrast to tocilizumab (an IL-6 inhibitor), it targets and inhibits the core mechanism in the pathogenesis of MAS, namely the hyperactive inflammasome loop
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03166-0. This may block inf-y